Banque Pictet & Cie SA Boosts Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Banque Pictet & Cie SA lifted its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 106.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,968 shares of the medical research company's stock after buying an additional 80,851 shares during the quarter. Banque Pictet & Cie SA's holdings in Edwards Lifesciences were worth $11,620,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. V Square Quantitative Management LLC grew its position in shares of Edwards Lifesciences by 2.3% during the 4th quarter. V Square Quantitative Management LLC now owns 15,374 shares of the medical research company's stock valued at $1,138,000 after purchasing an additional 348 shares in the last quarter. Bogart Wealth LLC increased its stake in Edwards Lifesciences by 38.2% in the 4th quarter. Bogart Wealth LLC now owns 92,768 shares of the medical research company's stock worth $6,868,000 after acquiring an additional 25,657 shares during the last quarter. Asset Management One Co. Ltd. raised its holdings in shares of Edwards Lifesciences by 1.0% in the 4th quarter. Asset Management One Co. Ltd. now owns 241,818 shares of the medical research company's stock valued at $18,294,000 after acquiring an additional 2,426 shares in the last quarter. Avestar Capital LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $203,000. Finally, Clarity Capital Partners LLC increased its position in shares of Edwards Lifesciences by 21.5% in the fourth quarter. Clarity Capital Partners LLC now owns 11,142 shares of the medical research company's stock worth $825,000 after purchasing an additional 1,973 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Down 0.7 %

Shares of EW traded down $0.52 on Tuesday, hitting $75.67. 4,937,936 shares of the stock traded hands, compared to its average volume of 4,574,817. The company has a market capitalization of $44.63 billion, a PE ratio of 10.92, a P/E/G ratio of 3.64 and a beta of 1.10. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The business has a 50 day simple moving average of $72.78 and a 200 day simple moving average of $69.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 2,500 shares of the firm's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares of the company's stock, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company's stock, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,489 shares of company stock worth $2,002,829. 1.29% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Truist Financial reissued a "hold" rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Morgan Stanley increased their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Bank of America upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Finally, Evercore ISI decreased their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.